Angelini Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Ancona Italy (1919)

Organization Overview

First Clinical Trial
2003
NCT00051441
First Marketed Drug
2010
trazodone (desyrel)
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

ANGELINI PHARMA | Angelini Pharma Portugal, Unipessoal, Lda | Aziende Chimiche Riunite Angelini Francesco S.p.A

Indications

Approved Indications


 

Mydriasis

Experimental Indications (Clinical Trials, Phases 1-4)


 

Bipolar Disorder (Phase 4)

Coronary Restenosis (Phase 2)

Depression (Phase 3)

Depressive Disorder (Phase 3)

Depressive Disorder, Major (Phase 3)

Diabetic Nephropathies (Phase 2)

Diabetic Neuropathies (Phase 2)

Disease (Phase 3)

Ductus Arteriosus, Patent (Phase 2)

Kidney Diseases (Phase 2)

Mucositis (Phase 3)

Pain (Phase 2)

Prostatitis (Phase 2)

Stomatitis (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 66
  • # of Trial APIs: 33